Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Thursday preview: BT's annual results in focus

(Sharecast News) - Full-year results from telecoms titan BT will be the headline-grabbing event of the day on Thursday, with investors keen to find out whether Allison Kirby's profitability drive has paid off. BT last updated the market in January, when it reiterated its guidance for 1-2% revenue growth over the 12 months ended 31 March, compared with the £20.80bn generated the year before.

Adjusted EBITDA is tipped to come in at £8.2bn, up marginally from £8.1bn previously, while normalised free cash flow (NFCF) is expected to by £1.5bn, up from £1.28bn.

The company also kept its mid-term targets for "sustained adjusted revenue growth and EBITDA growth ahead of revenue", enhanced by so-called "cost transformation" as well as limitations on capital spending.

As part of Kirby's plans announced last May, BT is also looking to lift NFCF to £2.0bn by FY27 and to £3.0bn by the end of the decade.

"Unlike its sector peer Vodafone, the BT Group share price has moved steadily higher over the last 12 months with the shares up over 75% in the last 12 months and back at levels last seen in the summer of 2022," said analyst Michael Hewson from MCH Market Insights.

"The gains have been slow and steady as new CEO Allison Kirby focussing on profitability with the Openreach fibre rollout continuing apace, with another 1m premises added to the FTTP build rate in Q3, bringing the total number to 17m with a view to reaching 25m by the end of next year."

As for economic data, business sentiment figures in Germany released by the IFO Institute will be closely watched in morning trade, while the latest jobless claims and existing-home sales data will be published Stateside in the afternoon.

Thursday May 22

INTERIMS

Impax Asset Management Group

INTERIM EX-DIVIDEND DATE

Bellway, BlackRock Greater Europe Inv Trust, Cardiff Property, Town Centre Securities

QUARTERLY EX-DIVIDEND DATE

Seplat Energy (DI), Vaalco Energy, Inc (DI)

INTERNATIONAL ECONOMIC ANNOUNCEMENTS

Continuing Claims (US) (13:30)

Existing Home Sales (US) (15:00)

IFO Business Climate (GER) (09:00)

IFO Current Assessment (GER) (09:00)

IFO Expectations (GER) (09:00)

Initial Jobless Claims (US) (13:30)

Q4

BT Group

FINALS

BT Group, easyJet, Johnson Matthey, Picton Property Income Ltd, Tate & Lyle

SPECIAL DIVIDEND PAYMENT DATE

Savills

AGMS

Aferian, Ashtead Technology Holdings, Bakkavor Group , Bank of Ireland Group (CDI), Coca-Cola Europacific Partners (DI), Convatec Group , Dunedin Income Growth Inv Trust, East Star Resources, Energean , Ferrexpo, Glenveagh Properties (CDI), Headlam Group, Henry Boot, Intertek Group, IQ-AI Limited, Judges Scientific, Legal & General Group, M Winkworth, Mercantile Investment Trust (The), Norman Broadbent , Petershill Partners , Pharos Energy , Quilter, Real Estate Investors, Sabre Insurance Group, Seneca Growth Capital Vct, Shaftesbury Capital, Shield Therapeutics, Spectris, Tullow Oil, Yu Group , Zinc Media Group, Zotefoams

TRADING ANNOUNCEMENTS

Convatec Group

UK ECONOMIC ANNOUNCEMENTS

Public Sector Net Borrowing (07:00)

FINAL DIVIDEND PAYMENT DATE

Aviva, Bridgepoint Group (Reg S) , ITV, Luceco , Savills, Secure Trust Bank

FINAL EX-DIVIDEND DATE

Andrews Sykes Group, Aptitude Software Group , Bunzl, Burford Capital NPV (DI), Fintel, Ingenta, Keller Group, Kingfisher, Midwich Group, Mincon Group (CDI), RHI Magnesita N.V. (DI), Science Group , Spire Healthcare Group, Whitbread

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.